Skip to main content

Day: November 26, 2019

The Lovesac Company to Announce Third Quarter Fiscal 2020 Earnings Results

STAMFORD, Conn., Nov. 26, 2019 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) today announced that its financial results for the third quarter of fiscal 2020 will be released before market open on Thursday, December 12, 2019. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results.Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (international callers please dial 201-493-6780) approximately 10 minutes prior to the start of the call. A live audio webcast of the conference call will be available online at investor.lovesac.com.A recorded replay of the conference call will be available within two hours of the conclusion of the call and can be accessed online at investor.lovesac.com for 90 days.About The Lovesac CompanyBased in Stamford, Connecticut,...

Continue reading

Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference

WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer, and William Ludlam, M.D., Ph.D., Senior Vice President of Clinical Development and Medical Affairs, will participate in an analyst-led fireside chat at the Piper Jaffray 31st Annual Healthcare Conference, which is being held December 3rd to 5th  in New York, New York.  Management is scheduled to present on Tuesday, December 3rd at 8:30 a.m. ET.A live audio webcast of the fireside chat will be available on the News and Investors section of Chiasma’s website at www.chiasma.com. A replay of the webcast will be available shortly after the conclusion of the presentation.  About...

Continue reading

SITO Mobile Announces Receipt of a NASDAQ Notice of Deficiency in Compliance with Certain Listing Rules

JERSEY CITY, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) — SITO Mobile Ltd. (NASDAQ: SITO) (“SITO” or the “Company”), an insights-driven Consumer Behavior and Location Sciences™ company, has received a notification letter from the Listing Qualifications Department of The NASDAQ Stock Market LLC (“NASDAQ”) dated November 20, 2019 indicating that the Company no longer meets the continued listing requirement related to the timely filing of its Form 10-Q for the period ended September 30, 2019 (the “Filing”).As a result of a delay in completing its Quarterly Report on Form 10-Q, the Company no longer complies with the Listing Rules (the “Rules”) for continued listing. Under NASDAQ Rules, the Company now has 60 calendar days to submit a plan to regain compliance and if the NASDAQ accepts SITO’s plan, it can grant an exception of...

Continue reading

NOTICE TO DISREGARD – VirTra, Inc.

TEMPE, Ariz., Nov. 26, 2019 (GLOBE NEWSWIRE) — We are advised by VirTra, Inc. (NASDAQ: VTSI) that journalists and other readers should disregard the news release, VirTra’s Law Enforcement Dog Encounters Training Approved by Department of Justice, issued Nov. 25, 2019 over GlobeNewswire.

Continue reading

Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference. The discussion will take place on Wednesday, December 4, 2019 at 11:30 a.m. ET (8:30 a.m. PT) in New York City.A live audio webcast and replay of the event will be available in the Investors section on the company’s website at www.crinetics.com.About Crinetics PharmaceuticalsCrinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization...

Continue reading

Financial Institutions, Inc. Announces Quarterly Cash Dividend

WARSAW, N.Y., Nov. 26, 2019 (GLOBE NEWSWIRE) — Financial Institutions, Inc. (the “Company”) (NASDAQ: FISI) announced today that its Board of Directors has approved a quarterly cash dividend of $0.25 per outstanding common share. The Company also announced dividends of $0.75 per share on its Series A 3% preferred stock and $2.12 per share on its Series B-1 8.48% preferred stock. All dividends are payable January 2, 2020, to shareholders of record on December 13, 2019.About Financial Institutions, Inc.Financial Institutions, Inc. provides diversified financial services through its subsidiaries Five Star Bank, SDN Insurance Agency, LLC (“SDN”), Courier Capital, LLC (“Courier Capital”) and HNP Capital, LLC (“HNP Capital”). Five Star Bank provides a wide range of consumer and commercial banking and lending services to individuals, municipalities...

Continue reading

Maha Energy AB (publ) (“Maha” or the “Company”) Nomination Committee for the AGM 2020

Maha Energy AB (publ)Strandvagen 5ASE-114 51 Stockholmwww.mahaenergy.ca                                                          Press releaseStockholmNovember 26, 2019                                                                                                     Maha Energy AB (publ) (“Maha” or the “Company”) Nomination Committee for the AGM 2020In accordance with the resolution at the Annual General Meeting (“AGM”) of Maha Energy AB on May 23, 2019, it was resolved that a Nomination Committee shall be appointed. The Nomination Committee shall comprise of the Chairman of the Board of Directors and three members appointed by the three largest shareholders by votes at the end of September each year.On September 30, 2019, the three largest shareholders, which desired to appoint a representative to the Nomination Committee, were Kvalitena...

Continue reading

Access-Power, Inc. is Pleased to Announce its Very FIRST Wall Street Interview

GRAND HAVEN, Mich., Nov. 26, 2019 (GLOBE NEWSWIRE) — Access-Power, Inc., (“ACCR or the Company”), a Grand Haven based medical marijuana clone corporation is pleased that we just completed our first interview as a public company, with a national PR company called Wall Street Analyzer.This interview was done on an unsolicited basis for the Company at no charge.  The interview was conducted over 30 minutes on a recorded line with Juan Costello, Senior Market Reporter for http://www.wallstreetanalyzer.com.  Among the highlights discussed were:Overview of the company’s products/services/projects, etc., discussing progress to date, and future milestones.History and background of company and key management as well as investment outlook.The recorded transcript details will be posted on The Wall Street Analyzer’s website for 3 days beginning...

Continue reading

Greenway Technologies Special Shareholders Meeting Scheduled for December 11, 2019

ARLINGTON, TEXAS, Nov. 26, 2019 (GLOBE NEWSWIRE) — Greenway Technologies, Inc. (OTCQB: GWTI) (the “Company”), an advanced gas-to-liquids (“GTL”) technology development company, today confirmed that a special shareholders meeting is scheduled for December 11, 2019, to be held at the Hilton Hotel, 2401 East Lamar Boulevard, Arlington, Texas, starting at 10:30 a.m. (CT). All shareholders of record as of October 29, 2019, have been mailed their proxy materials. Please review carefully the instructions on the proxy card regarding your voting options. All votes by proxy must be received by 11:59 p.m. (CT) December 10, 2019. Votes may be cast online: www.proxypush.com/GWTI or by telephone: 866.390.5236. Additional information may be found on the Company’s Proxy Statement DEF14A previously filed with the SEC on November 19, 2019.Shareholders,...

Continue reading

Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs

BEDFORD, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its proprietary adeno-associated viral vectors (AAVHSCs) crossed the blood-brain-barrier and blood-nerve-barrier in non-human primates (NHPs), highlighting their potential to deliver gene therapy for central and peripheral nervous system disorders. The publication includes the initial characterization of biodistribution with three of Homology’s 15 AAVHSCs, including their ability to transduce, or target, key cells following a single intravenous (I.V.) administration in NHPs. AAVHSCs are naturally occurring vectors originally isolated from human hematopoietic stem cells.“Many neurological diseases, including lysosomal storage and neuromuscular disorders, have...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.